TL;DR
While the glycoprotein 90K (encoded by the gene LGALS3BP) is a well-known "antiviral soldier" that fights HIV and Influenza, new research shows it is a bystander in the fight against SARS-CoV-2. Although 90K levels skyrocket in the serum of hospitalized COVID-19 patients—serving as a clear marker of the body's interferon response—functional lab tests reveal it fails to significantly restrict the virus's ability to infect human cells.
What Problem Does This Paper Address?
When the body detects a viral invader, it releases interferons (IFNs), which act as an alarm system to trigger hundreds of "Interferon-Stimulated Genes" (ISGs). These genes produce proteins designed to block various stages of the viral life cycle.
One such protein is 90K (LGALS3BP), a secreted glycoprotein known to interfere with how HIV-1 matures and how Influenza A spreads. Given that COVID-19 is characterized by a massive (and sometimes dysregulated) interferon response, researchers wanted to know: Is 90K part of our natural defense against SARS-CoV-2? If so, could it be used as a biomarker for disease severity or even a potential therapeutic?
Methods
The researchers took a multi-layered approach to track 90K from the hospital bedside to the petri dish:
- Clinical Quantitation: They analyzed 119 serum samples and 13 PBMC (peripheral blood mononuclear cell) samples from 44 hospitalized COVID-19 patients, comparing them to 42 age- and sex-matched healthy controls from a pre-pandemic cohort (NAKO).
- Bioinformatics: They "mined" existing single-cell RNA-sequencing (scRNA-seq) datasets to see exactly which cell types were expressing the LGALS3BP gene during infection.
- Functional Virology: They used "authentic" SARS-CoV-2 (not just harmless look-alikes) to infect various cell lines (HEK293T/ACE2, Calu-3, and Caco-2). They tested whether overexpressing 90K inside these cells or adding purified 90K protein to the outside could stop the virus.
Datasets
- Pa-COVID-19 Study: A longitudinal cohort of hospitalized patients at Charité - Universitätsmedizin Berlin.
- NAKO (German National Cohort): A large-scale population study used to provide healthy, pre-pandemic control samples.
- Published scRNA-seq Datasets: Specifically, a "Dual Center Cohort Study" of PBMCs and a separate study of respiratory specimens from COVID-19 patients.
Key Insights and Ideas
- The Secretion Shift: Interestingly, while 90K protein levels were high in the serum of patients, they were actually lower in the PBMCs compared to healthy controls. This suggests that during COVID-19, blood cells aren't just making more 90K; they are working overtime to pump it out into the extracellular space.
- Cell-Specific "Shouting": Bulk mRNA analysis didn't show a huge jump in LGALS3BP expression, but the single-cell data revealed the truth: the gene is specifically and intensely upregulated in monocytes, dendritic cells, and plasmablasts.
- The Bystander Effect: The most significant "aha" moment was the disconnect between expression and function. In many viral infections, an ISG being "up" means it's "working." Here, 90K is a robust biomarker of the global interferon response, but it appears to be an "innocent bystander" that SARS-CoV-2 has evolved to ignore or bypass.
- Model Matters: While 90K showed a tiny inhibitory effect in engineered HEK293T cells, it had zero effect in Caco-2 cells (a more naturally susceptible model). This highlights the danger of over-interpreting results from highly artificial cell systems.
Key Results
- Serum Levels: 90K concentrations were significantly higher in COVID-19 patients than in controls ($p < 0.0001$).
- Severity Correlation: The highest 90K levels were found in patients with severe disease (WHO grade 5), and levels generally declined as patients recovered.
- In Vitro Failure: In functional assays, neither overexpressing 90K nor adding it exogenously consistently inhibited SARS-CoV-2. In Caco-2 cells, 90K had no impact on viral RNA levels, protein expression, or the infectivity of released particles.
- Interferon Marker: The study confirmed that while SARS-CoV-2 infection itself doesn't trigger LGALS3BP in lung cells (Calu-3), treating those cells with Interferon-alpha does, confirming 90K's status as a classic ISG.
Limitations and Future Work
The authors acknowledge that their PBMC protein analysis was based on a relatively small cohort. Furthermore, while they proved 90K doesn't directly restrict the virus in a dish, they haven't ruled out its role in the broader immune system. 90K is known to modulate NK cell and CD8+ T-cell activity; it is possible that 90K helps the body fight COVID-19 by "tuning" the cellular immune response rather than by blocking the virus directly. Future studies could investigate these indirect immunomodulatory effects.
Summary updated